8 and control of tuberculosis: a call to action,” The Lancet, vol. 375, no. 9732, pp. 2179–2191, 2010. [12] T. A. Ghebreyesus, M. Kazatchkine, M. Sidibe´, and H. Nakatani, “Tuberculosis and HIV: time for an intensiﬁed response,” The Lancet, vol. 375, no. 9728, pp. 1757–1758, 2010. [13] S. S. Abdool Karim, K. Naidoo, A. Grobler et al., “Timing of initiation of antiretroviral drugs during tuberculosis therapy,” New England Journal of Medicine, vol. 362, no. 8, pp. 697–706, 2010. [14] F.-X. Blanc, T. Sok, D. Laureillard et al., “Earlier versus later start of antiretroviral therapy in HIV-infected adults with tu- berculosis,” New England Journal of Medicine, vol. 365, no. 16, pp. 1471–1481, 2011. [15] D. V. Havlir, M. A. Kendall, P. Ive et al., “Timing of anti- retroviral therapy for HIV-1 infection and tuberculosis,” New England Journal of Medicine, vol. 365, no. 16, pp. 1482–1491, 2011. [16] S. S. Abdool Karim, K. Naidoo, A. Grobler et al., “Integration of antiretroviral therapy with tuberculosis treatment,” New England Journal of Medicine, vol. 365, no. 16, pp. 1492–1501, 2011. [17] Ministry of State for Planning N.D., and Vision 2030, Kenya, Poverty Reduction Strategy Paper, International Monetary Fund, 2010. [18] Kericho District Hospital, Ministry of Health, Patient Reg- istries, 2011. [19] The Government of Kenya, September 2011, http://www.state- housekenya.go.ke/government/ministries.htm. [20] Ministry of Health, Government of Kenya, September 2011, http://www.statehousekenya.go.ke/government/health.htm. [21] “The United States President’s Emergency Plan for AIDS Relief,” September 2011, http://www.pepfar.gov/. [22] The Kenya Medical Research Institute (KEMRI), September 2011, http://www.kemri.org/. [23] U.S. Military HIV Research Program (MHRP), September 2011, http://www.hivresearch.org/home.php. [24] National AIDS and STI Control Programme (NASCOP), Ministry of Health, Guidelines for Antiretroviral Drug Therapy in Kenya, Ministry of Health, 2005. [25] National AIDS and STI Control Programme (NASCOP), Min- istry of Health, Kenya National Clinical Manual for ART Pro- viders, Ministry of Health, 2007. [26] National AIDS and STI Control Programme (NASCOP), Min- istry of Health, National Manual for the Management of HIV- Related Opportunistic Infections and Related Conditions, BAL- TECH EQUIPMENTS LTD, 2008. [27] National AIDS and STI Control Programme (NASCOP), http://nascop.or.ke/index.php. [28] Division of Leprosy, Tuberculosis, and Lung Diseases, DLTLD Guidelines on management of Leprosy and Tuberculosis, Min- istry of Public Health and Sanitation, 2009. [29] Division of Leprosy, Tuberculosis, and Lung Diseases (DLTLD), http://www.nltp.co.ke/. [30] D. Shaﬀer and J. Maswai, “Kericho District Hospital Ministry of Health/President’s Emergency Plan for AIDS Relief Com- bined TB/HIV Clinic: a Retrospective, Anonymous Clinical Record Review of Progress to Date (RV215, WRAIR #1347, KEMRI NRP#017),” 2010. [31] R. D. Moore, J. C. Keruly, K. A. Gebo, and G. M. Lucas, “An improvement in virologic response to highly active antiretro- viral therapy in clinical practice from 1996 through 2002,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 39, no. 2, pp. 195–198, 2005. AIDS Research and Treatment [32] N. R. Gandhi, A. Moll, A. W. Sturm et al., “Extensively drug- resistant tuberculosis as a cause of death in patients co- infected with tuberculosis and HIV in a rural area of South Africa,” Lancet, vol. 368, no. 9547, pp. 1575–1580, 2006.